Doximity — Key Risks

Revenue Is Highly Dependent on a Small Number of Pharmaceutical Brand Customers

Doximity generates most of its revenue from pharmaceutical manufacturer marketing budgets, and that spending is concentrated among a relatively small number of customers and agencies. Crucially, the company does not typically sign long-term contracts with these customers, meaning spending can be cut, redirected, or renegotiated at any time. When a drug loses patent protection, marketing budgets for that brand can disappear quickly — the filing notes this has already happened in the past.

Member Engagement Is the Foundation Everything Else Is Built On

The entire business model depends on doctors and other medical professionals actively using the platform. If member engagement declines — whether because a competitor offers better tools, privacy concerns emerge, or the platform simply stops feeling useful — pharmaceutical and health system customers lose their reason to advertise there. The company must continuously earn physician trust while also monetizing that audience, a tension it explicitly calls its "physicians first" philosophy.

No Long-Term Customer Contracts Creates Recurring Revenue Uncertainty

Most Marketing Solutions customers can walk away or renegotiate at renewal. Larger pharmaceutical companies operate with brand-level budgets, meaning even a strong relationship with one brand does not guarantee business from other brands in the same company's portfolio. The filing explicitly warns that ongoing renegotiations have already resulted in fee reductions, and macroeconomic pressures — including tariffs and potential recession — could accelerate customer spending cuts.

Workflow Solutions Products Are Unproven and Face Serious Competition

Products like telehealth and AI-based scheduling tools are described as "immature and volatile." These areas face direct competition from established players including Zoom, Microsoft Teams, Teladoc, and emerging AI healthcare tools. If these products do not gain meaningful adoption, the company's ambitions to diversify beyond marketing revenue stall.

Dual-Class Share Structure Leaves Outside Investors With Little Say

Class B shares carry ten votes each versus one vote for publicly traded Class A shares. As of March 31, 2025, insiders holding Class B shares control approximately 79% of voting power. This means executives and directors can effectively decide on board composition, acquisitions, and other major corporate actions without needing approval from the investors who bought shares on the open market. This structure is locked in until at least 2031.

Healthcare Regulatory Changes Could Shrink the Telehealth Opportunity

Several favorable telehealth reimbursement rules introduced during the COVID-19 public health emergency have persisted, boosting usage of Doximity's network. However, the filing acknowledges these policies could be reversed. If states roll back Medicaid and commercial insurance parity for telehealth, demand for that part of the platform could drop meaningfully.

Concentration Risk From Pharmaceutical Brand Losses

Beyond customer-level concentration, Doximity faces brand-level concentration within customers. A single blockbuster drug going off-patent can wipe out the marketing spend associated with it entirely. The filing confirms this scenario has already caused revenue declines in the past, and it could happen again as drug patent cliffs approach across the industry.